Most Medicare enrollees likely were not paying a monthly average of $400 — as President Joe Biden stated — before the insulin cap took effect. However, because costs and other factors result in widely varying prices, some Medicare enrollees might have paid that much in a given month.
With artificial intelligence in health care on the rise, eye screenings for diabetic retinopathy are emerging as one of the first proven use cases of AI-based diagnostics in a clinical setting.
Did the price of insulin go down? It’s not quite that simple. On this episode of “An Arm and a Leg,” producer Emily Pisacreta explores recent changes to the cost of the diabetes medication.
Doctors, patients, and hospitals have railed for years about the prior authorization processes that health insurers use to decide whether they’ll pay for patients’ drugs or medical procedures. The Biden administration announced a crackdown in January, but some state lawmakers are looking to go further.
Subscribe to The Podcast by KevinMD. Catch up on old episodes! We sit down with David Ahn, an endocrinologist. Join us as we delve into the impact of weight-loss drugs, the role of incretin medications, and their potential to reshape our approach to ob…
At the peak of the coronavirus crisis in 2020, American policymakers were faced with the critical challenge of how to encourage as many Americans as possible to be tested for and vaccinated against the COVID-19 virus. Fortunately, Congress rose to this…
Since Ozempic entered the cultural zeitgeist, I have been overwhelmed with requests from my patients – both those who meet criteria to start the medication and those who do not – for this new class of “miracle” drug. While it does work like…
California’s Medicaid program is making it easier for people with diabetes to obtain the supplies and equipment they need to manage their blood sugar, partly by relaxing preauthorization requirements that can cause life-threatening delays.
It’s a busy day in the emergency department. The waiting room is full, and we are short-staffed. I just read an email from administration that morning about how our treat and release times are “slipping,” and in the same breath, they …
The patient was a typical one in my primary care practice, and for those of you in my field, one familiar to you as well. Jim, as we will call him, was a middle-aged, obese male with a history of hypertension, hyperlipidemia, and diabetes, whose most c…
